15 results on '"Izzi GC"'
Search Results
2. AIEOP SNC 99 treatment protocol for standard risk medulloblastoma: preliminary results
- Author
-
Basso, E, Angelini, P, Sandri, A, Sardi, N, Bertin, D, Ricardi, U, Burnelli, R, DI CATALDO, Andrea, Bernini, G, Abate, M, Garrè, Ml, Perilongo, G, Fidani, P, Izzi, Gc, Mascarin, M, Iaria, G, D'Ambrosio, A, Zanazzo, G, CORDERO DI MONTEZEMOLO, L, and Madon, E.
- Published
- 2002
3. Proposal of guidelines for the treatment of infective complicatious in pediatric oncology: Therapy of febrile neutropenia (Proposte dilinea guida per il trattamento delle complicanze infettive in oncologia pediatrica: Terapia empirica della neutropenia febbrile)
- Author
-
Viscoli, Claudio, Castagnola, E, Caniggia, M, De Sio, L, Garaventa, A, Giacchino, M, Indolfi, P, Izzi, Gc, Manzoni, P, Rossi, Mr, Santoro, N, Zanazzo, Ga, and Masera, G.
- Published
- 1999
4. Italian guidelines for management of infectious complications in pediatric oncology: empirical entimicrobial therapy of febrile neutropenia
- Author
-
Viscoli, Claudio, Castagnola, E, Caniggia, M, DE SIO, L, Garaventa, A, Giacchino, M, Indolfi, P, Izzi, Gc, Manzoni, P, Rossi, Mr, Santoro, N, Zanazzo, G, and Masera, G.
- Published
- 1998
5. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry
- Author
-
Giampaolo Arcamone, Claudio Gambini, Claudio Favre, Giuliana Cangemi, Fiorina Casale, Guido Pastore, Gian Carlo Izzi, Giulio Andrea Zanazzo, Riccardo Haupt, Roberto Luksch, Bruno De Bernardi, Arcangelo Prete, Anna Rita Gigliotti, Alberto Garaventa, Alessandro Jenkner, Maurizio Bianchi, Elisabetta Viscardi, Stefano Parodi, Andrea Di Cataldo, Paolo D'Angelo, Haupt, R, Garaventa, A, Gambini, C, Parodi, S, Cangemi, G, Casale, Fiorina, Viscardi, E, Bianchi, M, Prete, A, Jenkner, A, Luksch, R, DI CATALDO, A, Favre, C, D'Angelo, P, Zanazzo, Ga, Arcamone, G, Izzi, Gc, Gigliotti, Ar, Pastore, G, and DE BERNARDI, B.
- Subjects
Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Adolescent ,Survival ,Kaplan-Meier Estimate ,Risk Assessment ,Neuroblastoma ,Recurrence ,Risk Factors ,medicine ,Humans ,Registries ,Survivors ,Stage (cooking) ,Child ,Survival rate ,Neoplasm Staging ,Proportional Hazards Models ,Chi-Square Distribution ,Proportional hazards model ,business.industry ,Incidence ,Incidence (epidemiology) ,Infant, Newborn ,Infant ,Italian Neuroblastoma Registry ,Survival Rate ,Treatment Outcome ,Standardized mortality ratio ,Italy ,Oncology ,Child, Preschool ,Relative risk ,Cohort ,Disease Progression ,Female ,business ,Chi-squared distribution - Abstract
Purpose To describe treatment, clinical course, and survival of a cohort of Italian patients with neuroblastoma. Patients and Methods The study includes data from 2,216 children (age 0 to 14 years) diagnosed between 1979 and 2005. Overall survival (OS) was analyzed by clinical and biologic features at presentation and periods of diagnosis: 1979 to 1984, 1985 to 1991, 1992 to 1998, and 1999 to 2005. The relative risk of second malignant neoplasm (SMN) was assessed by the standardized incidence ratio (SIR), with the Italian population selected as referent. Results Yearly patient accrual increased over time from 58 to 102. Patients age 0 to 17 months represented 45.6% of the total population, and their incidence increased over time from 36.5% to 48.5%. The incidence of stage 1 patients increased over time from 5.8% to 23.2%. A total of 898 patients (40.5%) developed disease progression or relapse, 19 patients developed SMN, and two patients developed myelodysplasia. The cumulative risk of SMN at 20 years was 7.1%, for an SIR of 8.4 (95% CI, 5.1 to 13.2). A total of 858 patients (39%) died (779 of disease, 71 of toxicity, six of SMN, and two of tumor-unrelated surgical complications). Ten-year OS was 55.3% (95% CI, 53.0% to 57.6%) and increased over time from 34.9% to 65.0%; it was significantly better for females and patients age 0 to 17 months at diagnosis, with extra-abdominal primary, and stage 1 and 2 disease. OS improved significantly over time in stage 1 and 3 patients. In patients with stage 4 disease, the improvement occurred between the first and second time cohorts (6.7% v 23.5%), but not afterward. Conclusion The outcome of children with neuroblastoma has progressively improved. Long-term survivors bear a significant risk of SMN.
- Published
- 2010
6. Clinical outcomes of rhabdomyosarcoma and Ewing's sarcoma of the head and neck in children.
- Author
-
Gradoni P, Giordano D, Oretti G, Fantoni M, Barone A, La Cava S, Ferri A, Sesenna E, Ferri T, and Izzi GC
- Subjects
- Adolescent, Child, Child, Preschool, Combined Modality Therapy methods, Drug Therapy, Female, Humans, Male, Prognosis, Radiotherapy, Retrospective Studies, Surgical Procedures, Operative, Treatment Outcome, Head and Neck Neoplasms therapy, Rhabdomyosarcoma therapy, Sarcoma, Ewing therapy
- Abstract
Objective: To review our experience and critically evaluate treatment strategy and results in children with head and neck rhabdomyosarcoma and Ewing's sarcoma., Methods: Retrospective charts review of children affected by non-orbital rhabdomyosarcoma or Ewing's sarcoma of the head and neck who were treated at our institution from January 1996 to August 2009., Results: Seven consecutive children with head and neck rhabdomyosarcoma or Ewing's sarcoma were identified. Four children had rhabdomyosarcoma, 3 children had Ewing's sarcoma. Regions involved were: cheek, ethmoid and maxillary sinuses, nasopharynx, middle ear/mastoid and frontal bone. In one case, surgery was performed as primary treatment modality; the other children were treated firstly with chemotherapy. Three patients underwent surgical resection after chemotherapy, while 4 patients received radiotherapy. Five children are disease free after a median of 7.7 years from initial diagnosis. Two patients relapsed after 10 and 29 months from initial diagnosis respectively; despite the administration of additional therapy both children died of disease., Conclusion: Treatment for rhabdomyosarcoma and Ewing's sarcoma consists in a multimodal therapy involving chemotherapy, radiotherapy and surgery. The optimum use, timing and intensity of these three treatments are still matters of international debate. Chemotherapy in association with radiotherapy has proven capable to obtain local and distant control of disease. But when surgery is unfeasible or fails in radicality, local control is difficult without radiotherapy. Despite additional therapeutic efforts, prognosis of relapsing disease remains poor., (Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
7. Atipical Kawasaki disease with coronary aneurysm in infant.
- Author
-
Dodi I, Raggi V, Verna M, Tchana B, Vignali D, Bandello MA, Lacava S, Izzi GC, and Agnetti A
- Subjects
- Anticoagulants therapeutic use, Cardiac Catheterization, Coronary Aneurysm diagnosis, Coronary Aneurysm therapy, Coronary Angiography, Diagnosis, Differential, Drug Therapy, Combination, Echocardiography, Follow-Up Studies, Humans, Immunologic Factors therapeutic use, Infant, Male, Mucocutaneous Lymph Node Syndrome diagnosis, Mucocutaneous Lymph Node Syndrome therapy, Ultrasonography, Interventional, Coronary Aneurysm etiology, Mucocutaneous Lymph Node Syndrome complications
- Abstract
Kawasaki disease is an acute febrile disease of unknown etiology, characterized by systemic vascular inflammation involving the small and medium sized arteries, with a predilection for the coronary arteries. It represents the leading cause of acquired heart diseases in children in developed countries. Diagnosis, difficult because of the clinical characteristics of the disease with typical signs and symptoms appearing sequentially and not simultaneously, may be even more complicated in case of unusual presentation, leading to delay in recognition, particularly in infant in whom a higher incidence of coronary arteries aneurysms has been reported. A high index of suspicion of Kawasaki disease must be maintained in case of prolonged fever in these patients. Timely appropriate treatment is essential to avoid severe sequels. We report the case of a 2 months old male infant with persistent febrile episode, transferred to us from another institution, who presented on echocardiography giant aneurysms on both coronary arteries.
- Published
- 2011
- Full Text
- View/download PDF
8. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry.
- Author
-
Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, Viscardi E, Bianchi M, Prete A, Jenkner A, Luksch R, Di Cataldo A, Favre C, D'Angelo P, Zanazzo GA, Arcamone G, Izzi GC, Gigliotti AR, Pastore G, and De Bernardi B
- Subjects
- Adolescent, Chi-Square Distribution, Child, Child, Preschool, Disease Progression, Female, Humans, Incidence, Infant, Infant, Newborn, Italy epidemiology, Kaplan-Meier Estimate, Male, Neoplasm Staging, Neuroblastoma diagnosis, Neuroblastoma therapy, Proportional Hazards Models, Recurrence, Registries, Risk Assessment, Risk Factors, Survival Rate, Time Factors, Treatment Outcome, Neuroblastoma mortality, Survivors statistics & numerical data
- Abstract
Purpose: To describe treatment, clinical course, and survival of a cohort of Italian patients with neuroblastoma., Patients and Methods: The study includes data from 2,216 children (age 0 to 14 years) diagnosed between 1979 and 2005. Overall survival (OS) was analyzed by clinical and biologic features at presentation and periods of diagnosis: 1979 to 1984, 1985 to 1991, 1992 to 1998, and 1999 to 2005. The relative risk of second malignant neoplasm (SMN) was assessed by the standardized incidence ratio (SIR), with the Italian population selected as referent., Results: Yearly patient accrual increased over time from 58 to 102. Patients age 0 to 17 months represented 45.6% of the total population, and their incidence increased over time from 36.5% to 48.5%. The incidence of stage 1 patients increased over time from 5.8% to 23.2%. A total of 898 patients (40.5%) developed disease progression or relapse, 19 patients developed SMN, and two patients developed myelodysplasia. The cumulative risk of SMN at 20 years was 7.1%, for an SIR of 8.4 (95% CI, 5.1 to 13.2). A total of 858 patients (39%) died (779 of disease, 71 of toxicity, six of SMN, and two of tumor-unrelated surgical complications). Ten-year OS was 55.3% (95% CI, 53.0% to 57.6%) and increased over time from 34.9% to 65.0%; it was significantly better for females and patients age 0 to 17 months at diagnosis, with extra-abdominal primary, and stage 1 and 2 disease. OS improved significantly over time in stage 1 and 3 patients. In patients with stage 4 disease, the improvement occurred between the first and second time cohorts (6.7% v 23.5%), but not afterward., Conclusion: The outcome of children with neuroblastoma has progressively improved. Long-term survivors bear a significant risk of SMN.
- Published
- 2010
- Full Text
- View/download PDF
9. A monosymptomatic Melkersson-Rosenthal syndrome in an 8-year old boy.
- Author
-
Dodi I, Verri R, Brevi B, Bonetti L, Balestrier A, Saracino A, Akamin R, Izzi GC, Vanelli M, and Sesenna E
- Subjects
- Child, Humans, Male, Melkersson-Rosenthal Syndrome diagnosis
- Abstract
Melkersson-Rosenthal Syndrome (MRS) is a systemic neuro-mucocutaneous granulomatous disease, characterized in its classical form by a triad of recurrent facial nerve paralysis, swelling of the lips and lingua plicata. However, this classical triad is rarely present, while the monosymptomatic or oligosymptomatic forms are more frequent. The presence of two or one of the manifestations mentioned above, with granulomatous cheilitis in the biopsy, is sufficient to make the diagnosis of monosymptomatic or oligosymptomatic form of MRS. This syndrome is very rare in childhood, instead, it is more frequent in young adults between the second and third decades of life. We present the case of an 8 years old boy who was brought to us because of a non painful swelling of the upper lip, associated with gingival hypertrophy, that had persisted for more than two months. Given the negative results of the hemato-chemical and instrumental assessments, we performed an upper lip biopsy whose histological study showed granulomatous cheilitis. We diagnosed this case as a monosymptomatic MRS and administered an intralesional steroid therapy using triamcinolone, with complete recovery.
- Published
- 2006
10. Cerebral venous sinus thrombosis in childhood: clinical aspects and neurological and cognitive long-term outcome in three cases.
- Author
-
Buccino G, Cossu G, De Fanti A, Manotti C, Izzi GC, and Mancia D
- Subjects
- Child, Child, Preschool, Dyslexia psychology, Fever pathology, Fever psychology, Humans, Magnetic Resonance Imaging, Male, Nervous System Diseases pathology, Neurologic Examination, Neuropsychological Tests, Protein C metabolism, Cognition physiology, Nervous System Diseases etiology, Sinus Thrombosis, Intracranial pathology, Sinus Thrombosis, Intracranial psychology
- Abstract
We report clinical findings, risk factors and neurological and cognitive long-term outcome in three Italian children aged 7, 8 and 5, respectively, who experienced cerebral venous sinus thrombosis (CVST). All children presented with headache, associated to nausea, vomiting and papilloedema. None suffered from epileptic seizures. In two of them a paresis of the sixth cranial nerve with diplopia was found. Diagnosis was confirmed by magnetic resonance imaging angiography (angio MRI) in all cases. In all patients plasma levels of protein C, protein S, antithrombin III (AT III), antiphospholipid antibodies (ApA) and homocysteine were detected. Furthermore, factor V Leiden mutation, prothrombin mutation G20210A and MTHFR mutation were searched for. A Protein C reduction was detected in all patients at onset; this finding, however, was not confirmed at follow-up in all of them. At one-year follow-up, neurological examination was normal in all children and neuropsychological assessment, aimed at excluding linguistic and non-linguistic cognitive deficits, revealed normal performances in two of them. In the third child, cognitive assessment confirmed a previously diagnosed developmental dyslexia.
- Published
- 2004
- Full Text
- View/download PDF
11. Epidemiological aspects of human rotavirus infection in children hospitalized with acute gastroenteritis in an area of northern Italy.
- Author
-
Medici MC, Martinelli M, Arcangeletti MC, Pinardi F, De Conto F, Dodi I, Virdis R, Abelli LA, Aloisi A, Zerbini L, Valcavi P, Calderaro A, Bernasconi S, Izzi GC, Dettori G, and Chezzi C
- Subjects
- Adenovirus Infections, Human epidemiology, Adenoviruses, Human isolation & purification, Caliciviridae Infections epidemiology, Child, Child, Preschool, Comorbidity, Diarrhea, Infantile virology, Feces virology, Female, Gastroenteritis virology, Hospitalization, Humans, Infant, Italy epidemiology, Male, Norovirus isolation & purification, Picornaviridae isolation & purification, Picornaviridae Infections epidemiology, Prevalence, Rotavirus isolation & purification, Seasons, Diarrhea, Infantile epidemiology, Gastroenteritis epidemiology, Rotavirus Infections epidemiology
- Abstract
Human rotavirus (HRV) is recognized as the most common cause of severe gastroenteritis in children under 5 years of age. Due to the lack of recent reports about the surveillance of HRV infection in Italy, in this study we assessed the prevalence rate of HRV infection on 1,340 stool samples belonging to 1,264 pediatric patients hospitalized with acute gastroenteritis in the period January 2000--December 2002. The stool samples were submitted to virological investigations by electron microscopy (EM) and conventional cell culture, as well as from January 2002 by RT-PCR for norovirus detection. Reovirus-like particles observed by EM were identified by electropherotyping. Single HRV infections were detected in 302 cases (23.9%, ranging from 19.1% in 2000 to 30.2% in 2001). Mixed infections were observed in 28 cases in which HRV was found to be associated with adenovirus in 16 cases (1.3%), with picornavirus in 4 (0.3%), and with norovirus in 8 (2.1% of the 388 cases examined in 2002). The 3 major epidemic periods of HRV infections were March--May 2000 (66 cases), December 2000--May 2001 (128 cases) and September 2001--April 2002 (105 cases) with peaks in March, January and March, and January, respectively. In the periods of major incidence, single HRV infection accounted even for 52.5% of the gastroenteritis cases monthly examined. According to age distribution, 68.9% (208 cases) of HRV infected children was under 4 years (69.6%: 230/330 cases, including mixed infections) and 16.9% (51 cases) was in the 5-12-year age-group. The epidemiological aspects of HRV infection, also compared to other enteric virus infections, will contribute to assess the magnitude of the problem of HRV in different settings and to devise strategies for intervention.
- Published
- 2004
12. Diamond-Blackfan anemia: report of seven further mutations in the RPS19 gene and evidence of mutation heterogeneity in the Italian population.
- Author
-
Ramenghi U, Campagnoli MF, Garelli E, Carando A, Brusco A, Bagnara GP, Strippoli P, Izzi GC, Brandalise S, Riccardi R, and Dianzani I
- Subjects
- Adult, Amino Acid Substitution, Base Sequence, Child, Cohort Studies, DNA chemistry, DNA genetics, DNA Mutational Analysis, Fanconi Anemia pathology, Female, Genetic Heterogeneity, Genotype, Humans, Italy, Male, Mutagenesis, Insertional, Mutation, Phenotype, Point Mutation, Sequence Deletion, Fanconi Anemia genetics, Ribosomal Proteins genetics
- Abstract
Diamond-Blackfan anemia (DBA) is a congenital disease characterized by defective erythroid progenitor maturation and physical malformations. Most cases are sporadic, but dominant or, more rarely, recessive inheritance is observed in 10% of patients. Mutations in the gene encoding ribosomal protein (RP) S19 have recently been found in 25% of patients with either the dominant or the sporadic form. DBA is the first human disease due to mutations in a ribosomal structural protein. Families unlinked to this locus have also been reported. In an investigation of 23 individuals, we identified eight different mutations in 9 patients. These include five missense, one frameshift, one splice site defect, and one 4-bp insertion in the regulatory sequence. Seven mutations are new; one has so far been found in 8 patients and is a relatively common de novo event. Two mutations are predicted to generate a truncated protein. We also report the prevalence of RPS 19 mutations in the Italian DBA population, as shown by an analysis of 56 patients. No genotype-phenotype correlation was found between patients with the same mutation. The main clinical applications for molecular analysis are clinical diagnosis of patients with an incomplete form of DBA and testing of siblings of a patient with a severe form so as to avoid using those who carry a mutation and a silent phenotype as allogeneic stem cell donors., (Copyright 2000 Academic Press.)
- Published
- 2000
- Full Text
- View/download PDF
13. Italian guidelines for the management of infectious complications in pediatric oncology: empirical antimicrobial therapy of febrile neutropenia.
- Author
-
Viscoli C, Castagnola E, Caniggia M, De Sio L, Garaventa A, Giacchino M, Indolfi P, Izzi GC, Manzoni P, Rossi MR, Santoro N, Zanazzo GA, and Masera G
- Subjects
- Child, Fever complications, Humans, Neutropenia complications, Anti-Bacterial Agents therapeutic use, Infections complications, Infections drug therapy, Neoplasms complications, Practice Guidelines as Topic
- Abstract
The Italian Association for Paediatric Haematology and Oncology prepared a guideline document aimed at unifying and rationalising as much as possible the management of febrile neutropenia in children with cancer, because of the potential impact of these procedures on hospital costs and on the development of antibiotic resistance. Before starting anti-infective therapy, at least 2 blood cultures, a throat swab, urine-culture, and cultures from any suspected infected site, should be performed. Routine chest X-rays at onset of febrile neutropenia are probably not necessary, in absence of respiratory signs. At the present time, the safer option probably remains the combination of a beta-lactam and an aminoglycoside, and treating febrile neutropenia outside of hospital should be considered an investigational approach. The choice of the most appropriated regimen for each institution should be based also on the local bacteriological statistics and patterns of bacterial resistance. Antibiotic toxicity and cost should be other important factors. Every subsequent addition or substitution of antibiotics should be based on objective signs of clinical deterioration. The only accepted empirical modification is empirical antifungal therapy, while the empirical addition of a glycopeptide antibiotic cannot be recommended.
- Published
- 1998
- Full Text
- View/download PDF
14. Fallout from Chernobyl. Not all health problems seen close to Chernobyl can be attributed to radiation.
- Author
-
Butturini A, Izzi GC, Benaglia G, Lloyd D, Pass B, and Gale RP
- Subjects
- Child, Environmental Exposure, Humans, Male, Ukraine epidemiology, Lymphocytes radiation effects, Power Plants, Radioactive Fallout, Radioactive Hazard Release
- Published
- 1994
15. Pulmonary syndrome and intravenous high-dose desferrioxamine.
- Author
-
Castriota Scanderbeg A, Izzi GC, Butturini A, and Benaglia G
- Subjects
- Adolescent, Child, Deferoxamine adverse effects, Humans, Infusions, Intravenous, Deferoxamine administration & dosage, Pulmonary Fibrosis chemically induced, Thalassemia drug therapy
- Published
- 1990
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.